HAEMATO AG / Key word(s): Personnel
HAEMATO AG: HAEMATO AG: The Supervisory Board and the Executive Board have agreed that Mr Uwe Zimdars will leave the Executive Board of HAEMATO AG on June 30, 2020.
25-Jun-2020 / 18:31 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Mr Zimdars is currently Executive Board Member of HAEMATO AG and Supervisory Board Member of M1 Kliniken AG. Due to the takeover of shares in HAEMATO AG by M1 Kliniken AG as of July 1, 2020, it is not possible to excercise both functions in parallel.
The Supervisory Board of HAEMATO AG would like to thank Mr Zimdars for his successful engagement and the good cooperation.
HAEMATO AG, founded in 1993, is a pharmaceutical company focusing on the growing markets of high-priced specialty pharmaceuticals in the indication areas of oncology and HIV as well as other chronic diseases.
HAEMATO AG is listed in the Basic Board (Open Market) of the Frankfurt Stock Exchange. Key figures on the HAEMATO AG share:
25-Jun-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||+49 (0)30 897 30 86 70|
|Fax:||+49 (0)30 897 30 86 79|
|Listed:||Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange|
|EQS News ID:||1079449|
|End of Announcement||DGAP News Service|